Early access to human data to de-risk drug development
Genoskin is a TechBio company that leverages immunology to de-risk drug and vaccine development, by enabling earlier access to human data.
Our platform uses bio-stabilized and immunocompetent ex-vivo human skin to elucidate efficacy and toxicity of self-injected biotherapeutics.
Combined with next-generation transcriptomics, multiplexed proteomics and artificial intelligence, we generate actionable human data, significantly reducing the costs, length and risks associated with drug development.